The Patent Finder

Novaliq GmbH

46 patents currently held · Updated Nov 18, 2026
9 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3
Ending by 2030
Nov 2029
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 27, 2026
    The maintenance fee for Pharmaceutical compositions for use in the therapy of blepharitis (US 11,684,589) comes due Dec 27, 2026. Unpaid by Jun 28, 2027, it lapses early.
  • 2 fees due Feb 6 to 15, 2027 · next Feb 6
  • 1 fee due Apr 22, 2027
    The maintenance fee for Methods of Treating Ocular Disorders Using Semifluorinated Alkanes (US 10,449,164) comes due Apr 22, 2027. Unpaid by Oct 22, 2027, it lapses early.
  • 2 fees due Jul 7 to 26, 2027 · next Jul 7
  • 2 fees due Aug 11 to 13, 2027 · next Aug 11
  • 1 fee due Sep 3, 2027
    The maintenance fee for Semifluorinated Alkane Compositions (US 10,576,154) comes due Sep 3, 2027. Unpaid by Mar 3, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 2 of the patents on this record were granted since Aug 20, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 8,986,738Inhalative and Instillative Use of Semifluorinated Alkanes as an Active Substance Carrier in the Intrapulmonary Area
In force
 · High confidence
In forceHigh confidence
US 8,796,340Pharmaceutical composition comprising propofol
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,614,178Pharmaceutical composition for treatment of dry eye syndrome
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,525,062Pharmaceutical composition for treatment of increased intraocular pressure
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,555,953Pharmaceutical composition for treatment of increased intraocular pressure
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,324,757Pharmaceutical composition for treatment of increased intraocular pressure
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,968,678Liquid pharmaceutical composition for the delivery of active ingredients
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,064,944Liquid pharmaceutical composition for the treatment of a posterior eye disease
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,045,996Pharmaceutical composition for treatment of increased intraocular pressure
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,241,900Liquid pharmaceutical composition for the treatment of a posterior eye disease
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 46 patents shown.
Pro members see all 46.
Pro members: see all 46 patents
Also on record, not counted in the 46: 9 patents in force now held by others · 2 lapsed for an unpaid fee · 2 ended at full term · 2 surrendered on reissue. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

8 pending · 5 abandoned · 16 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited